Radioactive 'Seek and Destroy' drug tested for tough prostate cancer

NCT ID NCT04868604

Recruiting now Disease control Sponsor: Clarity Pharmaceuticals Ltd Source: ClinicalTrials.gov ↗

Summary

This study is testing a new two-part treatment for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. First, a radioactive scanning drug finds the cancer. Then, a related radioactive therapy drug is given to target and damage those specific cancer cells. The main goals are to see if the treatment is safe and if it can shrink tumors and lower PSA levels.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BAMF Health
RECRUITING

Grand Rapids, Michigan, 49503, United States

Contact
East Jefferson General Hospital
NOT_YET_RECRUITING

River Ridge, Louisiana, 70123, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States

Contact

Contact
Washington University School of Medicine at Barnes-Jewish Hospital
RECRUITING

St Louis, Missouri, 63110, United States

Contact
Weill Cornell Medicine at New York-Presbyterian
RECRUITING

New York, New York, 10021, United States

Contact
XCancer
RECRUITING

Omaha, Nebraska, 68130, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROSTATIC NEOPLASMS, CASTRATION-RESISTANT